Ibandronic acid

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Ibandronic acid
Ibradronic Acid Structural Formulae.png
Systematic (IUPAC) name
{1-hydroxy-3-[methyl(pentyl)amino]propane-1,1-diyl}bis(phosphonic acid)
Clinical data
AHFS/Drugs.com International Drug Names
Licence data EMA:Link, US FDA:link
Pregnancy cat. C (US)
Legal status Prescription only
Routes Oral, intravenous
Pharmacokinetic data
Bioavailability 0.6%
Protein binding 90.9 to 99.5%
Metabolism Nil
Half-life 10 to 60 hours
Excretion Renal
CAS number 114084-78-5 YesY
ATC code M05BA06
PubChem CID 60852
DrugBank DB00710
ChemSpider 54839 YesY
KEGG D08056 YesY
Chemical data
Formula C9H23NO7P2 
Mol. mass 319.229 g/mol
 N (what is this?)  (verify)

Ibandronic acid (INN) or ibandronate sodium (USAN), marketed under the trade names Boniva® in the USA, Bondronat® in Europe, Bonviva® in Asia, and ADRONiL by Searle in Pakistan. Ibandronate is a potent bisphosphonate drug used in the prevention and treatment of osteoporosis.[1]

It may also be used to treat hypercalcemia (elevated blood calcium levels). Global sales in 2008 were 1.1B CHF ($1.0B USD at 01/01/2009 exchange rates).[2]

Medical uses[edit]

Ibandronate is indicated for the treatment and prevention of osteoporosis in post-menopausal women. Men should not take ibandronate unless they are participating in clinical trials.[3] In May 2003, the U.S. Food and Drug Administration (FDA) approved Ibandronate as a daily treatment for post-menopausal osteoporosis. The basis for this approval was a three-year, randomized, double-blind, placebo-controlled trial women with post-menopausal osteoporosis. Every participant also received daily oral doses of calcium and 400IUs [international units] of vitamin D. At the study's conclusion, both doses significantly reduced the occurrence risk of new vertebral fractures by 50–52 percent when compared to the effects of the placebo drug.

Adverse effects[edit]

In 2008, the U.S Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain.[4] A study conducted by the American Society of Bone and Mineral Research concluded that long term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [5]


External links[edit]